scholarly journals Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection

2021 ◽  
Vol 30 (162) ◽  
pp. 210194
Author(s):  
Ruben J. Mylvaganam ◽  
Joseph I. Bailey ◽  
Jacob I. Sznajder ◽  
Marc A. Sala
Keyword(s):  
Pulmonary Fibrosis ◽  
Respiratory Morbidity ◽  
Term Outcome ◽  
Cross Sectional ◽  
Long Term Outcome ◽  
Health Crisis ◽  
Clinical Registries ◽  
Morbidity Data ◽  
Key Aspects

Acute manifestations of SARS-CoV-2 infection continue to impact the lives of many across the world. Post-acute sequelae of coronavirus disease 2019 (COVID-19) may affect 10–30% of survivors of COVID-19, and post-acute sequelae of COVID-19 (PASC)-pulmonary fibrosis is a long-term outcome associated with major morbidity. Data from prior coronavirus outbreaks (severe acute respiratory syndrome and Middle East respiratory syndrome) suggest that pulmonary fibrosis will contribute to long-term respiratory morbidity, suggesting that PASC-pulmonary fibrosis should be thoroughly screened for through pulmonary function testing and cross-sectional imaging. As data accumulates on the unique pathobiologic mechanisms underlying critical COVID-19, a focus on corollaries to the subacute and chronic profibrotic phenotype must be sought as well. Key aspects of acute COVID-19 pathobiology that may account for increased rates of pulmonary fibrosis include monocyte/macrophage–T-cell circuits, profibrotic RNA transcriptomics, protracted elevated levels of inflammatory cytokines, and duration of illness and ventilation. Mechanistic understanding of PASC-pulmonary fibrosis will be central in determining therapeutic options and will ultimately play a role in transplant considerations. Well-designed cohort studies and prospective clinical registries are needed. Clinicians, researchers and healthcare systems must actively address this complication of PASC to minimise disability, maximise quality of life and confront a post-COVID-19 global health crisis.

scholarly journals Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up

2018 ◽  
Vol 36 (33) ◽  
pp. 3315-3323 ◽  
Author(s):  
Sandra Lockmer ◽  
Bjørn Østenstad ◽  
Hans Hagberg ◽  
Harald Holte ◽  
Ann-Sofie Johansson ◽  
...  
Keyword(s):  
Optimal Timing ◽  
Indolent Lymphoma ◽  
First Line ◽  
Term Outcome ◽  
Cross Sectional ◽  
Term Survival ◽  
Long Term Outcome ◽  
New Therapy

Purpose For indolent lymphoma, the optimal timing, sequence, and choice of therapeutic regimens remain a matter of debate. In two Nordic Lymphoma Group randomized trials, symptomatic or clearly progressing patients were treated first line with a rituximab-containing regimen without chemotherapy. The purpose of this study was to assess long-term survival, risk of transformation, and need of new therapies. Methods Data were collected at cross-sectional follow-up for 321 patients with indolent lymphoma (84% with follicular lymphomas [FL]) included in one of two Nordic Lymphoma Group trials (accrual 1998 to 1999 and 2002 to 2008). All patients received first-line therapy with one or two cycles of four weekly infusions of rituximab 375 mg/m2, and 148 were randomly allocated to the addition of interferon alfa-2a. Follow-up data were retrieved from initial trial databases and medical records on repeated clinical evaluations. Results At the end of follow-up, 73% of patients were alive, with a median follow-up after random assignment of 10.6 years. Among all, 36% (38% with FL) had never needed chemotherapy. For patients with FL who required new therapy within 24 months because of early disease progression, the 10-year survival rate was 59% versus 81% for those with longer remission. Interferon was not shown to improve long-term outcome. Transformation was diagnosed in 20% of all patients (2.4% per person-year) and in 18% with FL. An additional malignancy was found in 12%. Conclusion Approximately one third of patients with symptomatic indolent lymphoma (30% with FL, 23% without FL) did not need new therapy in the long term after first-line rituximab without chemotherapy. In the entire cohort, 10-year survival was excellent with no major safety issues, which suggests that chemotherapy can be delayed safely in the majority of patients.

Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity

2020 ◽  
Vol 30 (5) ◽  
pp. 2669-2679 ◽  
Author(s):  
Nicola Sverzellati ◽  
Mario Silva ◽  
Valeria Seletti ◽  
Carlotta Galeone ◽  
Stefano Palmucci ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Forced Vital Capacity ◽  
Vital Capacity ◽  
Term Outcome ◽  
Long Term Outcome

Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study

2017 ◽  
Vol 81 ◽  
pp. 56-65 ◽  
Author(s):  
Liselotte M. Boerman ◽  
Saskia W.M.C. Maass ◽  
Peter van der Meer ◽  
Jourik A. Gietema ◽  
John H. Maduro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cardiac Function ◽  
Breast Cancer Survivors ◽  
Population Based ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Term Outcome ◽  
Cross Sectional ◽  
Long Term Outcome

Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study

2011 ◽  
Vol 41 (1) ◽  
pp. 50-58 ◽  
Author(s):  
P Mathiesen ◽  
H Hegaard ◽  
T Herlin ◽  
M Zak ◽  
FK Pedersen ◽  
...  
Keyword(s):  
Juvenile Dermatomyositis ◽  
Term Outcome ◽  
Cross Sectional ◽  
Long Term Outcome ◽  
Follow Up Study

scholarly journals Childhood Epilepsy with Centrotemporal Spikes: Clinical and Neuropsychological Outcomes 5 Years after Remission

Diagnostics ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 931
Author(s):  
Costanza Varesio ◽  
Martina Paola Zanaboni ◽  
Elisa Carlotta Salmin ◽  
Chiara Totaro ◽  
Martina Totaro ◽  
...  
Keyword(s):  
Ad Hoc ◽  
Economic Status ◽  
Behavioral Assessment ◽  
Positive Family History ◽  
Active Phase ◽  
Term Outcome ◽  
Cross Sectional ◽  
Long Term Outcome ◽  
Neuropsychological Outcomes

Although specific neuropsychological deficits have been recognized during the active phase of epilepsy with centrotemporal spikes (ECTS), the natural cognitive and neuropsychological history after remission has not been elucidated so far. We evaluated the natural cognitive and neuropsychological outcomes five years after disease remission and investigated possible predictors of long-term outcome among socio-demographic and electro-clinical variables. We performed an observational cross-sectional study. Electro-clinical characteristics during the active phase of epilepsy, as well as antiepileptic treatment and premorbid neurodevelopmental concerns were reviewed for 70 patients. At least five years after epilepsy remission, all patients were contacted, and 46 completed a structured questionnaire about patients’ current education and academic skills, general health, and parents’ socio-economic status. Among them, 23 patients underwent an ad hoc cognitive and neuropsychological protocol and emotional-behavioral assessment. Chi-square tests and t-tests were carried out to define the role of putative predictors of neuropsychological outcomes. Mean cognitive and neuropsychological performances appeared to be overall adequate, except for the dictation. Positive family history for epilepsy (p = 0.01769) and familial socioeconomic status (mother’s schooling (p = 0.04169), father’s schooling (p = 0.01939), mother’s income (p = 0.0262), father’s income (p = 0.01331)) were identified as predictors of outcomes. Our data suggest that ECTS with typical electro-clinical features depicts an overall preserved cognitive and neuropsychological long-term outcome. We suggest particular attention should be paid to patients with socio-economic disadvantage and familial history of epilepsy, as they may experience worse neurocognitive post-morbid performances.

scholarly journals Long-Term Outcome and Use of 6-Minute Walk Test in West Highland White Terriers with Idiopathic Pulmonary Fibrosis

2014 ◽  
Vol 28 (2) ◽  
pp. 379-385 ◽  
Author(s):  
L.I.O. Lilja-Maula ◽  
H.P. Laurila ◽  
P. Syrjä ◽  
A.K. Lappalainen ◽  
E. Krafft ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Walk Test ◽  
Term Outcome ◽  
Long Term Outcome ◽  
6 Minute Walk Test ◽  
Minute Walk

scholarly journals Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the German Craniopharyngioma Registry (HIT-Endo)

2018 ◽  
Vol 179 (5) ◽  
pp. 331-341 ◽  
Author(s):  
Svenja Boekhoff ◽  
Agnieszka Bogusz ◽  
Anthe S Sterkenburg ◽  
Maria Eveslage ◽  
Hermann L Müller
Keyword(s):  
Growth Hormone ◽  
Hormone Replacement ◽  
Cross Sectional Study ◽  
Long Term Effects ◽  
Childhood Onset ◽  
Survival Prognosis ◽  
Term Outcome ◽  
Cross Sectional ◽  
Long Term Outcome

Objective Quality of survival, prognosis and long-term outcome are often severely impaired in childhood-onset craniopharyngioma (CP) patients. Identification of risk factors for sequelae such as growth hormone (GH) deficiency is important for appropriate treatment and rehabilitation. Design In a cross-sectional study, 79 CP patients recruited in HIT-Endo before 2000 were analyzed according to GH substitution: (a) CP never GH treated (noGH); (b) CP GH treated only during childhood (pedGH); (c) CP under GH, initiated at adulthood (adultGH); (d) CP under GH during childhood and continued during adulthood (contGH). Methods Progression-free (PFS) and overall survival (OS), height, BMI, psychosocial and neuropsychological status (EORTC QLQ-C30, MFI-20). Results OS and PFS rates were similar in all subgroups. ContGH and pedGH CP presented with increases in height (P = 0.002; P = 0.0001) during long-term follow-up when compared with baseline. In all subgroups except for pedGH, increases in BMI were observed when compared with BMI at diagnosis. For emotional functionality and physical fatigue, adultGH CP showed worse (P = 0.037; P = 0.034) response (mean: 61.4%; 12.5%) when compared with pedGH CP (mean: 83.5%; 7.7%). Observed differences were not related to irradiation and hypothalamic involvement. In terms of psychosocial status, no differences were observed between subgroups. Conclusions We conclude that GH substitution was safe with regard to risk of tumor progression/relapse in CP. Growth was improved by GH, whereas the development of obesity was not influenced by GH substitution. However, early initiation of GH substitution after CP diagnosis might have beneficial effects on weight development and neuropsychological outcome.

The importance of cross-sectional remission in schizophrenia for long-term outcome: A clinical prospective study

2009 ◽  
Vol 115 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Lars Helldin ◽  
John M. Kane ◽  
Fredrik Hjärthag ◽  
Torsten Norlander
Keyword(s):  
Prospective Study ◽  
Term Outcome ◽  
Cross Sectional ◽  
Long Term Outcome

Neurodevelopment and Health-Related Quality of Life in Infants Born with Gastroschisis: A 6-Year Retrospective French Study

2016 ◽  
Vol 27 (04) ◽  
pp. 352-360 ◽  
Author(s):  
Meriem Zahed ◽  
Floriane Guimond ◽  
Karine Baumstarck ◽  
Alice Faure ◽  
Fabrice Michel ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Short Form ◽  
Tertiary Care ◽  
Outcome Data ◽  
Primary Objective ◽  
Term Outcome ◽  
Cross Sectional ◽  
Long Term Outcome

Introduction Quantify quality of life (QoL) outcomes in gastroschisis children is little assessed. The primary objective was to describe the long-term outcome of newborns with gastroschisis treated in three tertiary care hospitals of France in terms of neurodevelopment and QoL. Materials and Methods The study reported was a cross-sectional, descriptive multicentric retrospective study assessing the outcome of newborns with gastroschisis, born between January 1, 2009, and December 31, 2014, treated at two large and French level III neonatal intensive care units. Long-term outcome data were assessed by questionnaires sent to the infants' parents. Questionnaires explored global health, neurological development, and quality of life (overall assessment including socio-economic and medical), Age & Stages Questionnaire, infants' quality of life (KIDSCREEN), and quality of parents' life (General Questionnaire Short Form-36). Results In this study, 50% of the survivor's families answered the assessment form (n = 33). The average follow-up age was 40 months, ranging from 8 months to 6 years. Cases of simple gastroschisis more often had a normal score for “communication” (p = 0.033), while patients who received morphine for a longer duration had significantly lower scores for the items “communication” and “problem resolving” (p = 0.024 and p = 0.011, respectively). Children's QoL was significantly lower for patients with gestational age younger than 36 weeks (p = 0.023) and for patients born following “fetal cause delivery” (p = 0.022). Parents had a significantly higher physical composite score if their child underwent primary closure (p = 0.012). Conclusion Our analyses confirm the idea that cases of complex gastroschisis and preterm delivery may lead to poorer outcome. Such hindsight (40 months in mean) allowed for an interesting assessment of development long after the patient's initial hospitalization and to confirm these results, a standardized neuropsychological evaluation of patients should be done when at least 6 years old. An accurate assessment of the social environment and its impact on the development and QoL of children will be fundamental to avoid selection bias.

Sign in / Sign up

Export Citation Format

Share Document